A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
View/ Open
Author
Bleiberg, H.
Decoster, G.
de Gramont, A.
Rougier, P.
Sobrero, A.
Benson, A.
Chibaudel, B.
Douillard, J. Y.
Eng, C.
Fuchs, C.
Fujii, M.
Labianca, R.
Larsen, A. K.
Mitchell, E.
Schmoll, H. J.
Sprumont, D.
Zalcberg, J.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1093/annonc/mdx050Metadata
Show full item recordCitation
Bleiberg, H., G. Decoster, A. de Gramont, P. Rougier, A. Sobrero, A. Benson, B. Chibaudel, et al. 2017. “A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group.” Annals of Oncology 28 (5): 922-930. doi:10.1093/annonc/mdx050. http://dx.doi.org/10.1093/annonc/mdx050.Abstract
Background: In respect of the principle of autonomy and the right of self-determination, obtaining an informed consent of potential participants before their inclusion in a study is a fundamental ethical obligation. The variations in national laws, regulations, and cultures contribute to complex informed consent documents for patients participating in clinical trials. Currently, only few ethics committees seem willing to address the complexity and the length of these documents and to request investigators and sponsors to revise them in a way to make them understandable for potential participants. The purpose of this work is to focus on the written information in the informed consent documentation for drug development clinical trials and suggests (i) to distinguish between necessary and not essential information, (ii) to define the optimal format allowing the best legibility of those documents. Methods: The Aide et Recherche en Cancérologie Digestive (ARCAD) Group, an international scientific committee involving oncologists from all over the world, addressed these issues and developed and uniformly accepted a simplified informed consent documentation for future clinical research. Results: A simplified form of informed consent with the leading part of 1200–1800 words containing all of the key information necessary to meet ethical and regulatory requirements and ‘relevant supportive information appendix’ of 2000–3000 words is provided. Conclusions: This position paper, on the basis of the ARCAD Group experts discussions, proposes our informed consent model and the rationale for its content.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406755/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:33029776
Collections
- HMS Scholarly Articles [17921]
Contact administrator regarding this item (to report mistakes or request changes)